H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on uniQure (QURE) to $70 from $25 and keeps a Buy ...

H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

Lexaria Bioscience (NASDAQ:LEXX – Free Report) had its price target trimmed by HC Wainwright from $10.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...

H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years in PlacementTracker's Market ...

Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...

H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the ...

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

Fintel reports that on January 22, 2025, HC Wainwright & Co. initiated coverage of Worksport (NasdaqCM:WKSP) with a Buy recommendation. As of December 23, 2024, the average one-year price target ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a leader in blockchain infrastructure and technology, has announced its ...